Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.
作者信息
Casadevall Arturo, Joyner Michael J, Pirofski Liise-Anne
机构信息
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Clin Infect Dis. 2021 Aug 2;73(3):e540-e542. doi: 10.1093/cid/ciaa1213.
Abstract
摘要
相似文献
1
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.2019年冠状病毒病（COVID-19）抗体动力学对免疫及恢复期血浆治疗的影响
Clin Infect Dis. 2021 Aug 2;73(3):e540-e542. doi: 10.1093/cid/ciaa1213.
2
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
3
Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.新型冠状病毒肺炎患者恢复期血浆输注安全性更新的局限性
Mayo Clin Proc. 2020 Dec;95(12):2801-2802. doi: 10.1016/j.mayocp.2020.09.033. Epub 2020 Oct 1.
4
Covid-19 convalescent plasma and SARS-CoV-2 viral variants.新冠康复者血浆与严重急性呼吸综合征冠状病毒2病毒变体
Transfus Clin Biol. 2021 Aug;28(3):306. doi: 10.1016/j.tracli.2021.05.008. Epub 2021 May 29.
5
COVID-19 convalescent plasma therapy and immunodeficiency.新冠康复者血浆疗法与免疫缺陷
Transfus Clin Biol. 2021 Aug;28(3):306-307. doi: 10.1016/j.tracli.2021.05.007. Epub 2021 May 29.
6
[Convalescent plasma therapy in COVID-19 patients].[新冠病毒肺炎患者的恢复期血浆治疗]
Medicina (B Aires). 2021;81(2):306.
7
In Reply - Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.回复——关于COVID-19患者恢复期血浆输注安全性更新的局限性
Mayo Clin Proc. 2020 Dec;95(12):2802-2803. doi: 10.1016/j.mayocp.2020.09.032. Epub 2020 Oct 1.
8
Use of Convalescent Plasma in the Management of COVID-19.康复期血浆在新型冠状病毒肺炎治疗中的应用
Mo Med. 2021 Mar-Apr;118(2):118.
9
Convalescent plasma therapy in patients with COVID-19.新型冠状病毒肺炎患者的恢复期血浆治疗
Transfus Apher Sci. 2021 Feb;60(1):103017. doi: 10.1016/j.transci.2020.103017. Epub 2020 Nov 19.
10
High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality.2019冠状病毒病的高滴度恢复期血浆疗法与死亡率
Transfusion. 2021 Jun;61(6):1988-1990. doi: 10.1111/trf.16434. Epub 2021 May 26.
引用本文的文献
1
Exercise and Experiments of Nature.《自然的锻炼与实验》
Compr Physiol. 2023 Jun 26;13(3):4879-4907. doi: 10.1002/cphy.c220027.
2
Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks.高效且可持续的平台，用于制备高质量免疫球蛋白 G，作为应对新兴病毒爆发时的紧急治疗选择。
Front Immunol. 2022 May 17;13:889736. doi: 10.3389/fimmu.2022.889736. eCollection 2022.
3
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.快速灵活的平台，用于评估抗 SARS-CoV-2 抗体中和作用和刺突蛋白特异性抗病毒药物。
mSphere. 2021 Aug 25;6(4):e0057121. doi: 10.1128/mSphere.00571-21. Epub 2021 Jul 28.
4
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.恢复期血浆用于 COVID-19 的预防和治疗：系统评价和定量分析。
JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500.
本文引用的文献
1
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.46 例重症 COVID-19 患者接受免疫血浆治疗后的死亡率降低：一项概念验证性单臂多中心试验。
Haematologica. 2020 Dec 1;105(12):2834-2840. doi: 10.3324/haematol.2020.261784.
2
Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后中和抗体反应的纵向动力学。
Clin Infect Dis. 2021 Aug 2;73(3):e531-e539. doi: 10.1093/cid/ciaa1143.
3
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 型感染：2020 年 4 月 22 日至 5 月 12 日期间英国前 436 位供者的分析。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2001260.
4
Kinetics of viral load and antibody response in relation to COVID-19 severity.病毒载量和抗体反应动力学与 COVID-19 严重程度的关系。
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
5
SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.SARS-CoV-2 病毒载量和抗体反应：恢复期血浆疗法的案例。
J Clin Invest. 2020 Oct 1;130(10):5112-5114. doi: 10.1172/JCI139760.
6
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
7
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
8
Duration of immunity to norovirus gastroenteritis.诺如病毒胃肠炎的免疫持续时间。
Emerg Infect Dis. 2013 Aug;19(8):1260-7. doi: 10.3201/eid1908.130472.
9
Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting 'unnatural' immunity.利用免疫系统的冗余性：疫苗可通过引发“非天然”免疫来介导保护作用。
J Exp Med. 2003 Jun 2;197(11):1401-4. doi: 10.1084/jem.20030637.
10
Immune responses during measles virus infection.麻疹病毒感染期间的免疫反应。
Curr Top Microbiol Immunol. 1995;191:117-34. doi: 10.1007/978-3-642-78621-1_8.
Zotero 插件